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Polyneuropathy is a common and important chemotherapy-induced adverse effect which often leads to dose 
modifications and impact on patients’ quality of life.  Limited treatment options for prevention and 
management of this neuropathology stimulate further research on the topic. Recent attention has been focused 
on downregulation of glial glutamate transporter expression observed in spinal region of rodents treated with 
cancer chemotherapy drugs. Consequent extrasynaptic glutamate overflow could be considered a key element in 
neuropathic pathogenesis resulting in excessive activation of glutamate receptors and neuronal 
hyper-excitability, finally contributing to develop neuropathic condition. Recently, the onset of neuropathy in 
bortezomib treated rats could be prevented by preemptive administration of drugs promoting glial glutamate 
transporter expression and antagonism at mGlur5, a metabotropic receptor which reinforces glutamatergic 
transmission in presence of high extracellular glutamate concentrations. These findings point to glial-glutamate 
system dysregulation as a main mechanism in the pathogenesis of anticancer chemotherapy induced neuropathy. 
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Chemotherapy-induced peripheral neuropathy (CIPN) is a 
recurrent adverse effect related to anticancer chemotherapy 
treatment that involves platinum agents, vinca alkaloids, 
bortezomib, thalidomide, taxanes and epothilone analogs [1]. 
The onset of neuropathy during treatment with these drugs, 
results in chemotherapy dose reductions or early 
discontinuation detracting power to the therapy. Although 
CIPN frequently resolves completely after therapy, some 
patients had residual neuropathy even two or more years after 
the end of pharmacological treatment [2]. Therefore, CIPN is 
a cause of significant distress in cancer patients inducing 
decreased quality of life and reduced functional ability.  
Unfortunately, effective treatments for prevention and 
management of CIPN have not yet been found. Many of the 
agents used in clinical practice for treatment of CIPN are 
chosen based on extrapolated data from pharmacologic 
studies of more common non-chemotherapy-related 
neuropathic pain syndromes, such as painful diabetic 
neuropathy and postherpetic neuralgia. 
A recent study that examined the pharmacological agents 
currently used in CIPN, shows that clinical trials are 
inconclusive even in respect of symptomatic pharmacological 
agents used to treat CIPN as tricyclic antidepressants, 
gabapentin or other medications with the same mechanism of 
action although these agents are relatively successful in 
treating other neuropathic pain conditions [3]. This report also 
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does not recommend the use of different substances such as 
acetyl-l-carnitine, CaMg, glutathione and Vitamin E in 
clinical practice due to the lack of a clear consistency of their 
validity in the prevention and treatment of CIPN [3]. Presently, 
the mainstays of treating this neuropathy in clinical practice 
are confined to dose and treatment schedule modification [4].  
CIPN is relatively distinct from other forms of neuropathic 
pain in terms of the pathophysiology and symptomatology. 
This pathology often occurs as a sensory rather than motor 
neuropathy and is characterized by higher prevalence of 
numbness, tingling and pain that generally starts in the toes 
and fingers and expands proximally. The exact mechanisms 
underlying CIPN are still unclear. Channel dysfunction and 
changes in membrane polarization have been identified as a 
critical mechanism for the development of neuronal 
hyperexcitability and acute symptoms of CIPN, especially 
from platinum chemotherapeutics and proteasome inhibitors. 
However, proposed alterations in voltage-gated sodium and 
potassium channel kinetics do not adequately account for 
CIPN symptoms [5,6].  
Recent preclinical studies focused on chemotherapy 
induced glia alterations. A significant increase in astrocyte 
cell density in spinal cord was shown in oxaliplatin treated 
rats [7,8] . Astrocyte activation was observed within the spinal 
cord of paclitaxel [9,10] and bortezomib [11] treated rats. One 
way astrocytes affect neuronal function is through the 
excitatory aminoacid transporters (EAAT). Changes in the 
expression of glial glutamate transporters as glutamate 
transporter-1 (GLT-1) were examined in the spinal cord of 
rats with chemotherapy induced mechanical hyperalgesia 
[12,13]. Immunohistochemical studies showed that the 
expression of GLT-1 in the spinal dorsal horn was 
significantly decreased in paclitaxel/taxol treated rats as 
compared to controls [12,13]. 
Glutamate transport process has the ability to maintain 
stimulatory, but nontoxic, levels of free intrasynaptic 
glutamate nearby neurons [14].  Previous studies have shown 
the importance of these transporters in peripheral pain. 
Inhibition of glutamate transporters results in an elevation of 
spinal extracellular glutamate and spontaneous pain [15].   
Pharmacological blockade of GTs, including glial GTs,  in 
the spinal cord resulted in a hyperalgesic state in awake 
animals [15] and increased the activation of 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA), N-methyl-D-aspartate (NMDA) receptors [16,17] and 
group I metabotropic glutamate receptors (mGluRs) [18]. 
Neurophysiologic studies have also shown that impaired glial 
glutamate uptake and consequent extrasynaptic glutamate 
overflow resulted in excessive activation of glutamate 
receptors in the spinal dorsal horn from neuropathic rat [19,20]. 
Allosteric antagonist at the mGluR5, a receptor recruited 
only in presence of high extracellular glutamate 
concentrations, could effectively prevent the development of 
bortezomib induced neuropathy in rodent as shown by 
assessment of sensory nerve conduction velocity, an 
established neuropathy marker [21].  
These findings postulate that the abnormalities induced by 
anticancer chemotherapy drugs on glutamate transport 
process underlie polyneuropathy, resulting in the 
accumulation of extracellular glutamate in synaptic clefts, 
factor that determines the activation of neurons and influence 
neuronal excitability [22]. On inhibition of glutamate uptake, 
glial cells function like excitatory interneurons, releasing 
glutamate to activate postsynaptic neurons in spinal pain 
pathways and finally contributing to the development of 
neuropathic condition.  
Recently, CINP could be revoked when glutamate 
transporter expression and function was promoted in 
bortezomib treated rats [21]. Ceftriaxone is a beta-lactam 
antibiotic and its use has been shown to not affect 
bortezomib antitumor action in multiple myeloma cell lines 
[21]. In addition to its known antibacterial effect, ceftriaxone 
has the ability to stimulate the expression of EAATs, 
increasing transcription of the EAAT2 gene [23]. NF-kB 
binding site at the -272 position of the EAAT2 promoter was 
identified as responsible for the ceftriaxone-mediated 
EAAT2 activation in human tissue and a similar action could 
be realized in rodent through analogous EAAT1 gene 
transcription [24].  
It must be pointed out that glutamate modulator 
pharmacological agents were unable to revert neuropathic 
impairment and pain associated to this pathology if 
administered to rodent when CIPN was already established 
[21]. The consideration that arises from these experiments is 
that CIPN can be prevented but not revoked once the 
glutamatergic system was overactive.  Thus, preemptive 
co-administration of glutamate modulators with anticancer 
drugs is necessary to prevent CINP. 
Ceftriaxone is largely prescribed in clinical practice as 
beta-lactam antibiotic. Thus, translational therapy 
administration to a significant number of CINP patients 
might be undertaken to validate preclinical results. The 
implementation of drug discovery efforts has recently focused 
on specific activator of glutamate transporter to provide 
neuroprotection in several neurodegenerative diseases [25]. 
Specific modulation of pharmacological target with these 
molecules will expected to be of therapeutic benefit in CIPN 
prevention and management. 
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